NEW YORK (GenomeWeb News) – Nuclea Biotechnologies today said that it raised $4.2 million in its Series D round. The Pittsfield, Mass.-based company added that it plans to close the $5 million round on May 31.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.
The new Riken president outlines some of his plans for the institute.
The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.
An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.